Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million.
Thousands of patients with a particular form of breast cancer in England and Wales can be confident they will continue to have access to Pfizer's targeted therapy Ibrance, thanks to new gui
Bristol-Myers Squibb's Opdivo has shown efficacy when used as a post-surgery (adjuvant) treatment for patients with melanoma, extending the time before the disease recurrence or patient dea
A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has been shown to be more effective at improving progression-free survival than Bristol-Myers Squibb's immuno
Bristol-Myers Squibb's new immune checkpoint inhibitor combination Opdualag has only been on the US market for a few weeks but is already off to a "great start", according to chief executiv
Boehringer Ingelheim says it may have found the first therapy for diabetic macular ischaemia (DMI), a common and irreversible complication of the eye in people with diabet
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.